Skip to main content
. 2007 Nov 21;82(3):1591–1599. doi: 10.1128/JVI.01792-07

FIG. 1.

FIG. 1.

Dissection of MAb contributions to neutralization activity. Total, MAb-mediated, and patients' (autologous) antibody (Ab)-mediated neutralization activities (70% NT) against the heterologous virus JR-FL (A and B) and the autologous viruses (C and D) were evaluated for all 14 patients. Data are means from two to four independent experiments. (A and C) Representative profiles of neutralization activities of plasma from patient NAB04 against JR-FL (A) and the autologous virus of patient NAB04 (C), analyzed throughout the trial. The MAb infusion period and off-treatment phase (MAb washout) are indicated. Gray squares, viral load (VL; expressed as copies of HIV RNA/ml of patient plasma); black circles with solid lines, total neutralization activity in plasma (combined autologous-Ab and MAb activities); dashed lines, autologous-Ab activity. The calculated MAb NTs are shown in separate panels as dark red, orange, and green areas for 2G12, 2F5, and 4E10, respectively. The sum of the activities of all three MAbs is shown as a light blue area in the top panel. (B and D) Summary of total neutralization activity (black) and MAb-mediated neutralization activity (red) for each of the 14 individuals during the trial against JR-FL (B) and autologous viruses (D).